导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -21.71% | 4450/4773 |
| 近一周 | -3.64% | 4396/5462 |
| 近一月 | -2.11% | 1157/5421 |
| 近一季 | -9.94% | 3368/5209 |
| 近半年 | -28.62% | 4849/4920 |
| 近一年 | -16.62% | 3808/4366 |
| 近两年 | 27.68% | 2378/2954 |
| 近三年 | -3.21% | 1972/2253 |
| 成立以来 | 87.07% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.79% 2485/4961 |
-19.74% 4862/5312 |
- - |
- - |
| 2025 | 28.91% 1440/4813 |
6.09% 679/3635 |
-2.89% 3387/4076 |
17.82% 2425/4524 |
6.20% 371/4813 |
| 2024 | 3.14% 1941/3463 |
-0.08% 1071/2808 |
-8.16% 2174/3014 |
13.66% 2138/3129 |
-1.11% 1593/3463 |
| 2023 | -5.07% 712/2656 |
2.91% 1288/2280 |
-5.51% 1483/2385 |
2.53% 229/2515 |
-4.78% 1171/2655 |
| 2022 | -21.75% 1048/2207 |
-9.07% 309/1919 |
1.14% 1496/2016 |
-15.45% 1297/2113 |
0.63% 1470/2208 |
| 2021 | 40.14% 33/1822 |
15.98% 4/1255 |
8.54% 615/1330 |
21.65% 40/1466 |
-8.48% 1583/1822 |
| 2020 | - - |
- - |
8.90% 808/1067 |
8.38% 716/1164 |
7.94% 691/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 国泰中证钢铁ETF VS. 长安沪深300非周期A(740101) |